Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.7 (
plasmin
)
9,023
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activation of
plasmin
from its circulating precursor plasminogen is the mechanism of several clot-busting drugs used to clinically treat patients who have suffered a stroke; however,
plasmin
thus generated has been shown to activate platelets directly. There has been speculation as to whether
plasmin
interacts with the protease-activated receptors (PARs) because of its similarity in amino acid specificity with the classic platelet activator thrombin. We have investigated whether
plasmin
activates platelets via PAR activation through multiple complementary approaches. At concentrations sufficient to induce human platelet aggregation,
plasmin
released very little calcium compared with that induced by thrombin, the PAR-1 agonist peptide SFLLRN, or the
PAR-4
agonist peptide AYPGKF. Stimulation of platelets with
plasmin
initially failed to desensitize additional stimulation with SFLLRN or AYPGKF, but a prolonged incubation with
plasmin
desensitized platelets to further stimulation by thrombin. The desensitization of PAR-1 had no effect on
plasmin
-induced platelet aggregation and yielded an aggregation profile that was similar to
plasmin
in response to a low dose of thrombin. However,
PAR-4
desensitization completely eliminated aggregation in response to
plasmin
. Inclusion of the PAR-1-specific antagonist BMS-200261 inhibited platelet aggregation induced by a low dose of thrombin but not by
plasmin
. Additionally, mouse platelets naturally devoid of PAR-1 showed a full aggregation response to
plasmin
in comparison to thrombin. Furthermore, human and mouse platelets treated with a
PAR-4
antagonist, as well as platelets isolated from
PAR-4
homozygous null mice, failed to aggregate in response to
plasmin
. Finally, a protease-resistant recombinant
PAR-4
was refractory to activation by
plasmin
. We conclude that
plasmin
induces platelet aggregation primarily through slow cleavage of
PAR-4
.
...
PMID:Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. 1497 36
Plasmin is a major extracellular protease that elicits intracellular signals to mediate platelet aggregation, chemotaxis of peripheral blood monocytes, and release of arachidonate and leukotriene from several cell types in a G protein-dependent manner. Angiostatin, a fragment of
plasmin
(ogen), is a ligand and an antagonist for integrin alpha(9)beta(1). Here we report that
plasmin
specifically interacts with alpha(9)beta(1) and that
plasmin
induces of cells expressing migration recombinant alpha(9)beta(1) (alpha(9)-Chinese hamster ovary (CHO) cells). Migration was dependent on an interaction of the kringle domains of
plasmin
with alpha(9)beta(1) as well as the catalytic activity of
plasmin
. Angiostatin, representing the kringle domains of
plasmin
, alone did not induce the migration of alpha(9)-CHO cells, but simultaneous activation of the G protein-coupled protease-activated receptor (PAR)-1 with an agonist peptide induced the migration on angiostatin, whereas PAR-2 or
PAR-4
agonist peptides were without effect. Furthermore, a small chemical inhibitor of PAR-1 (RWJ 58259) and a palmitoylated PAR-1-blocking peptide inhibited
plasmin
-induced migration of alpha(9)-CHO cells. These results suggest that
plasmin
induces migration by kringle-mediated binding to alpha(9)beta(1) and simultaneous proteolytic activation of PAR-1.
...
PMID:Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1). 1524 68